Janux Therapeutics, Inc. (JANX) — Operating Cash Flow
| Fiscal Year | Operating Cash Flow | Change YoY |
|---|---|---|
| 2025 | -$82.23M | -87.7% |
| 2024 | -$43.81M | +13.4% |
| 2023 | -$50.58M | -17.8% |
| 2022 | -$42.92M | -152.8% |
| 2021 | -$16.98M | -288.6% |
| 2020 | -$4.37M | — |
| Fiscal Year | Operating Cash Flow | Change YoY |
|---|---|---|
| 2025 | -$82.23M | -87.7% |
| 2024 | -$43.81M | +13.4% |
| 2023 | -$50.58M | -17.8% |
| 2022 | -$42.92M | -152.8% |
| 2021 | -$16.98M | -288.6% |
| 2020 | -$4.37M | — |